Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis

Neumann, Bjoern; Foerster, Sarah; Zhao, Chao; Bodini, Benedetta; Reich, Daniel S.; Bergles, Dwight E.; Káradóttir, Ragnhildur Þóra; Lubetzki, Catherine; Lairson, Luke L.; Zalc, Bernard; Stankoff, Bruno; Franklin, Robin J.M.

Opin vísindi
→
IRIS
→
IRIS
→
Skoða verk

dc.contributor.author	Neumann, Bjoern
dc.contributor.author	Foerster, Sarah
dc.contributor.author	Zhao, Chao
dc.contributor.author	Bodini, Benedetta
dc.contributor.author	Reich, Daniel S.
dc.contributor.author	Bergles, Dwight E.
dc.contributor.author	Káradóttir, Ragnhildur Þóra
dc.contributor.author	Lubetzki, Catherine
dc.contributor.author	Lairson, Luke L.
dc.contributor.author	Zalc, Bernard
dc.contributor.author	Stankoff, Bruno
dc.contributor.author	Franklin, Robin J.M.
dc.date.accessioned	2022-08-26T01:04:19Z
dc.date.available	2022-08-26T01:04:19Z
dc.date.issued	2020-05-07
dc.identifier.citation	Neumann , B , Foerster , S , Zhao , C , Bodini , B , Reich , D S , Bergles , D E , Káradóttir , R Þ , Lubetzki , C , Lairson , L L , Zalc , B , Stankoff , B & Franklin , R J M 2020 , ' Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis ' , Cell Stem Cell , vol. 26 , no. 5 , pp. 617-619 . https://doi.org/10.1016/j.stem.2020.03.017
dc.identifier.issn	1934-5909
dc.identifier.other	43318775
dc.identifier.other	7498963f-1ca4-4bac-8888-cc14294f2fac
dc.identifier.other	85084118366
dc.identifier.other	32386552
dc.identifier.uri	https://hdl.handle.net/20.500.11815/3374
dc.description	The authors acknowledge the following support: The UK Multiple Sclerosis Society (MS50 to R.T.K., C.Z., and R.J.M.F.), The Adelson Medical Research Foundation (D.S.R., D.E.B., and R.J.M.F.), Intramural Research Program of NINDS/NIH (D.S.R.), European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Program (771411 to R.T.K.), The Lister Institute (R.T.K.), and a core support grant from the Wellcome and MRC to the Wellcome-Medical Research Council Cambridge Stem Cell Institute (203151/Z/16/Z to R.T.K. and R.J.M.F.). Publisher Copyright: © 2020 Elsevier Inc.
dc.description.abstract	Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.
dc.format.extent	3
dc.format.extent	554761
dc.format.extent	617-619
dc.language.iso	en
dc.relation	info:eu-repo/grantAgreement/EC/H2020/771411
dc.relation.ispartofseries	Cell Stem Cell; 26(5)
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	MS sjúkdómur
dc.subject	Molecular Medicine
dc.subject	Genetics
dc.subject	Cell Biology
dc.title	Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis
dc.type	/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version	Peer reviewed
dc.identifier.doi	10.1016/j.stem.2020.03.017
dc.relation.url	http://www.scopus.com/inward/record.url?scp=85084118366&partnerID=8YFLogxK
dc.contributor.department	Faculty of Medicine